Mergers & acquisitions
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.
Boston-based ABclonal Biotechnology acquired contract research organization (CRO) Yurogen Biosystems.
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
While public perception of the pharmaceutical industry is on an upswing among the general population due to rapid vaccine and therapeutic development during the COVID-19 pandemic, in the eyes of credit rating agencies, the industry is on a continued downward spiral.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
PRESS RELEASES